Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based Director operating in the Pharmaceutical space. If you think a Director is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Paul Agapow
Health Informatics Director of AstraZeneca
Originally a labcoat-wearing biochemist and immunologist, Paul fell sideways into using computers for biology, at first for evolutionary biology and infectious disease. In more recent years, his work has focused on precision medicine and biomedical analytics.
Follow Paul Agapow:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
_______
Vincenzo Garzya
Patient Centricity Excellence Director of AstraZeneca
Follow Vincenzo Garzya:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Claus Bendtsen
Executive Director of AstraZeneca
Claus Bendtsen heads Quantitative Biology as part of Discovery Sciences within AstraZeneca. His department provides global support in areas of informatics, mathematical modelling, image analytics and non-clinical statistics. Prior to joining AstraZeneca he held positions at Novartis and Merck & Co. Earlier in his career he co-founded three start-ups and worked in academia. He holds a Ph.D. in applied mathematics and an MBA.
Follow Claus Bendtsen:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Sheena Behn
Global Supply Director of AstraZeneca
Sheena Behn is an established global leader in the Pharmaceutical Industry with significant supply chain, manufacturing and development experience and expertise. She has worked at AstraZeneca for 20 years. Sheena is currently VP Therapy Area Supply (for CVRM/INA Therapy Areas) in Operations for AstraZeneca, and the Operations Executive Sponsor for Risk, based in the UK. She was previously based in Gothenburg as VP R&D Supply Chain (2013-2015), running the global group for Clinical Supply at AZ; and before that VP for Wuxi Manufacturing site for 3 years, based in China (2010-2012). Sheena is a Pharmacist who started her career working in London hospitals, before working in pharmaceutical development with GSK and then AZ before joining Operations in 2007.
Follow Sheena Behn:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Matthew Bonam
Pharmaceutical Project Director of AstraZeneca
Follow Matthew Bonam:
About AstraZeneca, AstraZeneca, AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Louise Almond
Associate Director, Process Sciences of Allergan
Follow Louise Almond:
About Allergan, Pharmaron: Allergan is a global pharmaceutical company.
Stefano Ragni
Director – Global Supply Chain Process Lead of GSK
Stefano Ragni is Global business process owner in GSK for Supply Chain Planning processes, including architecture, people’s roles & responsibilities, cross-functional integration and capability built to enable the business model. Stefano led similar programmes and held operational leadership roles for Integrated Business Planning and Demand Planning in other industries, such as FMCG (eg Heinz) and Automotive (eg Goodyear Dunlop). Beyond his integrated Supply Chain leadership skills, Stefano’s background includes roles in finance, capital engineering and systems implementation.
Follow Stefano Ragni:
About GSK: GSK Venture Fund is a Massachusetts-based venture capital fund focused on investments within the area of bioelectronics.
Adrian Phipps
Global SEO Director of GSK
Adrian is a highly experienced and transformational SEO professional with over 19 years hands-on experience. Starting his career with digital media agencies before progressing client side delivering digital and SEO solutions for the likes of Pfizer, BBC, Volvo, Eurotunnel, Saga and now GSK. Adrian’s most recent achievements have been to drive organic traffic for Saga from 300K sessions per month to over 1 million session per month in 18 months. Moreover, in the same time driving quick answer results from a standing start of 0 to now over 600.
Follow Adrian Phipps:
About GSK: GSK Venture Fund is a Massachusetts-based venture capital fund focused on investments within the area of bioelectronics.
Richard Ross
Founding Director & CSO of Diurnal Group
Richard Ross is a founding Director of Diurnal and Chief Scientific Officer and is contracted to perform work for the Group by the University pursuant to the terms of a secondment agreement and a research agreement. He is a Professor of Clinical Endocrinology and Head of the Academic Unit of Diabetes, Endocrinology and Metabolism at the University of Sheffield and was previously a Senior Lecturer at St. Bartholomew’s Hospital, London. Richard’s primary research interest is pituitary and adrenal disease with a particular focus on hormone replacement. His research has yielded over 200 papers, more than 30 granted patents and publications in Nature Medicine, Nature Reviews Endocrinology, Nature Genetics, The Lancet, The BMJ and PNAS. He has been a member of the editorial boards of Clinical Endocrinology and the Journal of Clinical Endocrinology and Metabolism and served as an elected member of the executive committees for the European Society of Endocrinology (Treasurer), the Society for Endocrinology and Growth Hormone Research Society.
Follow Richard Ross:
About Diurnal Group, University of Sheffield: Diurnal Group is an innovative pharmaceutical company creating high-value therapeutic drugs for use in the endocrine hormone area.
Elena Fernandez Kleinlein
Sr. Director Consumer Scientific Innovation of Johnson & Johnson
Elena is the Senior Director of Consumer Scientific Innovation at Johnson & Johnson Innovation. Her main responsibilities are scouting and evaluating early stage technologies and opportunities and managing external partnerships for the strategic areas within the Consumer Sector. Prior to this role, Elena was the Senior Director of R&D Global Topical Health Care for Johnson & Johnson Consumer & Personal Products. In this position, she was responsible for seeking innovative products and claims pipelines within the franchise and oversaw the product development program for iconic brands such as Band-Aid Adhesive Bandages, Johnson & Johnson’s Red Cross and other regional brands like Compeed, Neosporin and Bengay. Elena has grown in the Johnson & Johnson Family of Companies, previously holding roles of Senior Director R&D EMEA Topical Health, performing as the Worldwide Director Women’s Health R&D, and Manager Baby & Kids R&D EMEA for Johnson & Johnson in Germany. These positions have provided her an in-depth knowledge in Research & Development across different groups as well as launch & commercialization experience of different product categories. She has filed several patents. Elena holds a BS and MS in Food Science & Technology from Technical University Munich, Germany.
Follow Elena Fernandez Kleinlein:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Helene Finney
Director, Functional Screening of UCB
Helene joined UCB (then Celltech) in 1989 after 2 years at the MRC Laboratory of Molecular Biology Cambridge, and has gained expertise in a range of antibody technologies. Her PhD studies at UCB in gene therapy generated the first co-stimulation signal inclusive (now termed “second generation”) CAR-T cell constructs. She has led a variety of antibody technology teams & early stage therapeutic antibody discovery projects for oncology, bone, immunology/inflammation & CNS targets. Helene now leads the UCB Functional Screening project team; combining cutting edge antibody & screening technology to discover break-through bispecific antibody drugs across multiple therapeutic areas.
Follow Helene Finney:
About UCB, UCB: UCB Pharma is a biopharmaceutical and specialty chemical company.
Heresh Rezavandi
Ecosystem Strategic Intelligence Lead, Associate Director of UCB
Heresh Rezavandi is the associate director of ecosystem strategic alliance at [UCB Pharma](https://www.crunchbase.com/organization/ucb-pharma), a biopharmaceutical and specialty chemical company that develops therapeutics for central nervous system and immunological diseases.
Follow Heresh Rezavandi:
About UCB: UCB Pharma is a biopharmaceutical and specialty chemical company.
Gavin Wild
Associate Director of UCB
Follow Gavin Wild:
About UCB: UCB Pharma is a biopharmaceutical and specialty chemical company.
Anne Lenihan
Director Regulatory Affairs of Pfizer
Follow Anne Lenihan:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Lynsey Flitton
Associate Director Labeling Strategy Europe of AbbVie
Follow Lynsey Flitton:
About AbbVie: AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Dennis Engelke
Executive Director, Country Manager Switzerland & Austria of Jazz Pharmaceuticals
Dennis Engelke is the director of business analysis and insight at [Jazz Pharmaceuticals](https://www.crunchbase.com/organization/jazz-pharmaceuticals), an international biopharmaceutical company. Engelke holds an MBA from Uppsala University and an MBA from the University of Hamburg.
Follow Dennis Engelke:
About Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments.
Simon Barter
Commercial Director of Proveca
Simon Barter is a commercial director at Proveca. Simon is an experienced pharmaceutical professional having held several significant senior level roles including the head of Global Marketing capability for AstraZeneca, the head of the Global Commercial Innovation function. He has a track record of delivery in global marketing, innovation, corporate and portfolio strategy and operating company delivery. He has broad therapeutic experience having led the commercial therapy areas for Pain, Anaesthesia, Infection and Oncology. Simon has lived and worked across several European countries in sales and marketing roles, amassing first hand experience of several healthcare systems. Simon has a BSc (Hons) from London University and a Masters in Science of Management from Boston University.
Follow Simon Barter:
About Proveca: Proveca Ltd is a UK based pharmaceutical company.
Chris Wood
Non Executive Director of MiNA Therapeutics
Chris Wood has more than 20 years of experience in the biotechnology sector, having founded, managed and successfully exited 4 companies. Chris is Executive Chairman and Medical Director of NuCana. He was co-founder, Chairman and CEO of Bioenvision Inc from 1999, and under his leadership Bioenvision grew from a modest entrepreneurial venture to a leading biotech company (NASDAQ: BIV), with a market capitalisation of $345 million. Bioenvision was acquired by Genzyme Corporation in October 2007. Chris was co-founder of Medirace Ltd, a start up biotechnology company, which later became Medeva PLC, traded on the London Stock Exchange and the New York Stock Exchange, and was acquired by Celltech Group PLC (now UCB) for £554 million. Chris Wood is an honorary Professor at Imperial College London, holds an M.D. from the University of Wales School of Medicine and is a Fellow of the Royal College of Surgeons of Edinburgh. Chris Wood’s specialty interests are Cancer and Molecular Biology and he has acquired an international reputation for his published work in these areas.
Follow Chris Wood:
About Medannex Ltd, NuCana BioMed: MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms.
Tim Luker
Senior Director, External Innovation, Global External R&D of Eli Lilly
Follow Tim Luker:
About Eli Lilly: Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
Derek Marren
Director – Research IT – Global TA & Biology systems & Data Integration of Eli Lilly
Follow Derek Marren:
About AstraZeneca, Eli Lilly: Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
David Jackson
Agency Commercial Director of United Drug plc
Follow David Jackson:
About United Drug plc: United Drug plc ensures the right products are delivered to the right people at the right time, at the right price.
Peter Lemon
Purchasing Director, United Drug Sangers of United Drug plc
Peter was educated at Annadale Grammar School and when he left school at the age of 18, started working in the Pharmaceutical Sector in the UK as a Trainee Buyer. Most of Peter’s working life has been in the Pharmaceutical Distribution sector with over 40 years’ experience. Peter commenced employment with Sangers in 1993 as a Purchasing Manager and was appointed to the position of Purchasing Director in 1998. Peter is a member of Belvoir Park Golf Club and enjoys playing golf there on a regular basis. His other hobbies and interests include Hockey, Reading and Travel.
Follow Peter Lemon:
About United Drug plc: United Drug plc ensures the right products are delivered to the right people at the right time, at the right price.
Edwin Bleakley
Operations Director, Sangers of United Drug plc
Edwin was educated at Methodist College in Belfast. He was employed by the Northern Bank, Munster Simms and then AAH Pharmaceuticals as General Manager for 14 years before joining Sangers in 2000. Edwin has a keen interest in music and has been a church organist for many years, now playing in the church on the oldest Christian site in Ireland where St. Patrick started his mission, at Saul near Downpatrick. He has rescued and restored a 1954 Triumph TR2 sports car which he still enjoys driving. Edwin has a large garden which requires significant time commitment. Edwin has three grown up children, two living in Northern Ireland and one in Australia, and five grand-children.
Follow Edwin Bleakley:
About United Drug plc: United Drug plc ensures the right products are delivered to the right people at the right time, at the right price.
Richard Whitley
Member of the Board of Directors of Gilead Sciences
Whitley joined Gilead’s Board of Directors in 2008. He is a Distinguished Professor, Loeb Scholar Chair in Pediatrics; Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Senior Scientist, Cancer Research and Training Center; Associate Director for Clinical Studies, Center for AIDS Research; and Co-Director, Center for Emerging Infections and Emergency Preparedness (CEIEP) for the institution. Whitley has held responsibility for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, is a past President of the International Society of Antiviral Research, chairs the Board of Scientific Counselors for the National Center for Infectious Diseases of the U.S. Centers for Disease Control and Prevention and is President of the Board of the Infectious Diseases Society of America.
Follow Richard Whitley:
About : Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
Colleen Johnson
Associate Directorof Toxicology & Consultant of Spinifex Pharmaceuticals
Colleen brings over 20 years of experience in the area of toxicology. She holds a M.S. in Toxicology from University of Arizona as well as Board Certification (D.A.B.T.) and specializes in the development of nonclinical toxicology testing programs for new drugs. Her activities include preparation of toxicology summaries for Spinifex’s submissions in support of our development candidates, develops study protocols and monitors the company’s toxicology programs.
Follow Colleen Johnson:
About Spinifex Pharmaceuticals: Spinifex Pharmaceuticals is a clinical-stage biotechnology company specializing in the development of products for the treatment of pain.
Vibhor Gupta
Director and Founder of Pangaea Data
Vibhor is an entrepreneur in residence at Nexgen Capital Ventures where he is involved in deal flow and leading creative technological opportunties within Life Sciences following his breadth of experience in industry and academia over the last 16 years. Prior to this role, Vibhor has served in various positions ranging from technical bioinformatics roles, sales (of software technology products) and executive management. Vibhor started and built the European business for Quantum Secure, which was an enterprise software solutions provider and was successfully acquired in 2015. Most recently he served as a Senior Vice President at Seven Bridges Genomics which provides cloud (SaaS) based bioinformatics solutions for the Life Sciences industry. Vibhor has also worked as a management and technology consultant for Deloitte. His academic career focused on bioinformatics, epigenetics and molecular biology studies in oncology and infectious diseases. Vibhor has access to an extensive network in the industry and was recently honoured as an advisor to two prominent organisations, HealthEx and FrontLine Genomics. He was also a Technology Lead on ASIS’s UK committee, which is the largest professional body for CSOs and CISOs in the world.
Follow Vibhor Gupta:
About Pangaea Data: Pangaea Data provides a machine learning-based software solution making scientific and clinical data more meaningful.
Hazel Gorham
Director – Biosimilars Development of PRA Health Sciences
Follow Hazel Gorham:
About PRA Health Sciences: PRA Health Sciences provides product development and data solution services to pharmaceutical and biotechnology companies.
Benedicte Thiebaut
Technology Director of Medical Components of Johnson Matthey
Benedicte Thiebaut is the Technology Director of Medical Components at Johnson Matthey.
Follow Benedicte Thiebaut:
About Johnson Matthey: Johnson Matthey is an international speciality chemicals company, founded almost 200 years ago in London.
Soren Krogsgaard Thomsen
Co-Founder, CEO and Managing Director of BioMe Oxford
Soren is a medical scientist at the University of Oxford, with a background in the natural sciences and genetics research. He previously worked as a consultant for pharma and OBR consulting, and has published on his experiences as an academic entrepreneur. Soren’s current research is focused on translating large-scale genetic data into mechanisms for disease to inform new therapeutic strategies. He dreams of one day enabling similar population-wide microbiome studies using the platform technology under development at BioMe Oxford Ltd.
Follow Soren Krogsgaard Thomsen:
About BioMe Oxford, Vertex Pharmaceuticals: Unlocking your gut microbiome by developing a medical device for targeted and non-invasive sampling
Islam Pearson
Managing Director of Greenliving Pharma
Islam is the man in charge, the overseer, protector, and father figure. With his background in property development and renewable energy technologies, he tends to come at the business from the point of view of the customer, and regularly offers a wealth of knowledge to anyone interested. He lives for his work, and may or may not be a gymnast. We’re not quite sure yet.
Follow Islam Pearson:
About Greenliving Pharma: Greenliving Pharma is a nutraceutical company that distributes pharmaceutical products.
Ozgur Tuncer
CEO & Executive Director of Stablepharma Ltd
Ozgur Tuncer CEO & Executive Director – two decades of experience in the biopharmaceutical industry including working for blue chip companies such as Pfizer, IQVIA and Pharmacia. Most recently, he was Global Vice President in IQVIA, and strategic adviser to life sciences investors. In addition to his role in Stablepharma, Özgür is an Investment Partner with Ascension Ventures.
Follow Ozgur Tuncer:
About Stablepharma Ltd: An innovative Biotech, developing a wide range of reformulated thermostable and fridge free StablevaX vaccines
Adam George
UK Managing Director of GW Pharmaceuticals
Adam George has served as our Managing Director – UK since March 2017. Mr. George also acts as our Company Secretary. Prior to taking on his current role, Mr. George served as our Chief Financial Officer since 2012 and Financial Controller since 2007. Mr. George has previously occupied several senior finance roles within both public and privately-owned companies, most recently as Finance Director from 2004 to 2007 and as Group Financial Controller from 2001 to 2004 of Believe It Group Limited (now 4Com plc), a telecommunications service provider. Mr. George holds an BSc. in Biology from Bristol University and is qualified as a chartered accountant.
Follow Adam George:
About GW Pharmaceuticals: GW Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics.
Nativ Segev
Managing Director & Co Founder of MGC Pharmaceuticals
Nativ Segev is the Founder and Director of MGC Pharmaceuticals Ltd.
Follow Nativ Segev:
About MGC Pharmaceuticals: MGC Pharmaceuticals is a company founded with vision. A vision of globalizing the arena in which Cannabis, and specifically CBD.
Daniel Broughton
Director of Dr. Fox
Follow Daniel Broughton:
About : Online Doctors and Pharmacy Service
Tony Steele
Medical Director of Dr. Fox
Follow Tony Steele:
About : Online Doctors and Pharmacy Service
Jasbir Singh
Managing Director of HEL LTD
Follow Jasbir Singh:
About HEL LTD: HEL Ltd is a provider of automated and manual tools to clients in the pharmaceutical, and chemical industries.
Matt Worrall
Associate Director, Policy & Communication – Oncology of MSD
Matt has more than a decade of healthcare media relations and public affairs experience gained across medical professional bodies, NHS and provider sector. Before joining Portland he was a public affairs executive at ABPI and was Head of Communications at the Royal College of Surgeons. He saw the College through its engagement with the Health & Social Care Act 2012 and high-profile campaigning for the relaxation of the European Working Time Directive. Among his clients in recent years have been the NHS National Screening Committee, NHS England, BMI Healthcare, HCA International, Lilly, Amgen, UCB, Mundipharma, Apple and Alexion.
Follow Matt Worrall:
About MSD: MSD is a leading global biopharmaceutical company that provides medicines, vaccines, biologic therapies, and animal health products.
Karl Equi
Creative, Digital Director, and Executive Director of PMLiVE
Follow Karl Equi:
About PMLiVE: PMLiVE is an online network offering its users with the opportunity to discuss with their colleagues on issues of pharmaceutical market.
Jonathan Raven
Global Director, Customer Development, Clinical Services of Avantor
Follow Jonathan Raven:
About Avantor: Avantor is a provider of mission-critical products and services to customers in the life sciences and applied materials industries.
Dominic Farmer
Managing Director of Cisiv
Dominic Farmer has over 25 years experience in both healthcare technology and observational research. He set up Cisiv to provide technologies for use in real world research following extensive experience with leading global Pharma companies in the software development and implementation of large-scale global studies.
Follow Dominic Farmer:
About Cisiv: Cisiv is a developer of technology solutions for pharmaceutical companies.
Ruth Whittaker
Finance and Admin Director of Cisiv
Follow Ruth Whittaker:
About Cisiv: Cisiv is a developer of technology solutions for pharmaceutical companies.
Jiahao Huang
Co-founder, Director and CFO of Nuclera
A molecular biologist by trade, Jiahao has coordinated multi-national collaborative projects and experienced first hand the limitations of the current provision of DNA. This intimate knowledge of user requirements enables him to guide Nuclera’s commercial operations towards creating the right product for the right market. Jiahao holds a BSc from the University of California, Berkeley, and a PhD in Molecular Biology from the University of Cambridge.
Follow Jiahao Huang:
About Nuclera: Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis.
Mark Davies
Senior Director, Head of Digital and Multi Channel Marketing (International) of Zoetis
Mark has extensive experience in developing and executing successful digital business strategies in start-up, SME and Large Corporate environments.He was a Founder and Sales & Marketing Director of u-rooms ltd in 2009, prior to that he was the e-commerce and new media manager for FTSE 250 UNITE Group, a provider of student accommodation.
Follow Mark Davies:
About Zoetis: Zoetis is committed to research, combining to help protect the health of pets and farm animals and the productivity.
Michael O’Neill
Co-Founder and Director R&D of Inflection Biosciences
Michael O’Neill has more than 20 years’ experience working in the pharmaceutical industry. He was a Senior Research Scientist and Portfolio Manager at Eli Lilly for much of this time where he was responsible for developing project plans for the selection of projects and for their progression from discovery through to important development milestones. He established his own consulting business, Eolas, to help early stage companies to organize their research along commercial lines, becoming accomplished at building highly streamlined development plans. He has built consortia of commercial and academic groups to apply for major EU grants. Previously Dr. O’Neill was Head of Laboratory at Almirall and a Research Neuroscientist at Merck. He has authored over 80 papers, book chapters, patents and abstracts and is Honorary Visiting Senior Lecturer at the Science Policy Research Unit at the University of Sussex. He holds a BA Psychology from UCC and a PhD from QUB Belfast.
Follow Michael O’Neill:
About Inflection Biosciences: Inflection Biosciences is a company that develops small-molecule therapeutics for the treatment of cancer.
George Grigg
Marketing Director of Matrix
Follow George Grigg:
About Matrix: Matrix provides data integration and software for the healthcare and pharmaceutical sectors.
Oliver Nulty
Director of ONFAB
ONFAB Limited, (formerly CSP UK) was founded in 2004 Oliver Nulty CEng, MIMechE, MIET. Having held senior positions in Engineering, Project and Production management, Oliver has built up a wealth of valuable experience in the field of containment, working for blue chip companies such ICI and AstraZeneca. It was during this time that he realised the need for flexible containment and left to start up the business. He has since developed unrivalled and successful designs, that are being used sucessfully all over the world
Follow Oliver Nulty:
About ONFAB: ONFAB is a design and supply company that matched the values we expect and appreciate as a customer.
Catherine Beech
Board of Directors of Exonate
Follow Catherine Beech:
About : Exonate is a biotech company spun out of the University of Nottingham that is focused on alternative splicing of (VEGF) in ophthalmology.
Jonathan Moseley
Technical Director of CatSci
Jonathan obtained his BSc in Chemistry from Southampton University in 1986 before starting as a medicinal chemist for Merck Sharp and Dohme working on CNS projects for three years. He returned to academia in 1989 and completed his PhD from Cambridge University in 1992 on a thesis entitled Synthesis of Cerulenin Analogues with Prof. Jim Staunton. He returned to Merck Sharp and Dohme as a medicinal chemist for a further three years before moving to Zeneca (now AstraZeneca) as a process development chemist in 1996. Since then he has worked on the full range of pharmaceutical development projects from early route selection, kilo-lab and pilot plant scale-up, through to established manufacturing processes. His research interests include the application of new technologies to scale-up within pharmaceutical manufacture, notably in the use of microwaves. He has presented and published widely on both process development and microwave synthesis.
Follow Jonathan Moseley:
About CatSci: CatSci provides innovative process research and development services to emerging, mid-sized and large pharma.
Ed Turp
Facilities Director of CatSci
Ed completed a BSc in Applied Chemistry at Salford University in 1993 and stayed to complete his PhD in 1996 with Prof. Garry Procter on stereoselective additions to a,b-epoxy-aldehydes. On completion of his PhD Ed joined Zeneca (now AstraZeneca) as a chemist working in the Research Support Laboratory at Mereside. In 2000 he moved to the Avlon site as part of the commercial product support team. In 2006 Ed moved into process chemistry to work on mid-stage development projects. In 2008 Ed switched gears to join the Catalysis Facility where he has delivered significant improvement to the ways of working and has been heavily involved in the utilisation of physical organic techniques to improve reaction understanding.
Follow Ed Turp:
About CatSci: CatSci provides innovative process research and development services to emerging, mid-sized and large pharma.
Anna Harrington Morozova
Scientific and Regulatory Director of Regem Consulting
Follow Anna Harrington Morozova:
About Regem Consulting: Regem Consulting is a UK based drug development and regulatory consultancy.
Charles Hindson
Non Executive Director of Diaceutics
Follow Charles Hindson:
About Diaceutics: Diaceutics Group leverages analytics, software, services and consulting.
Andrew Marr
Managing Director of Marr Consultancy
30 years in the Pharmaceutical industry in Regulatory Affairs and Regulatory Operations. 10 years in Regulatory Affairs including UK, US, Preclinical and CMC regulatory roles. 15 years in Regulatory Operations with business-side responsibilities for the development, implementation and process optimisation of regulatory document management and publishing systems and electronic submission to regulatory agencies. 10 years at the forefront of standards and process development for electronic interchange between industry and regulator, on a worldwide basis. Strategy consultant, highly respected in the pharmaceutical sector. Leading consultant on the requirements and business processes for the Extended Eudravigilance Medicinal Product Dictionary (XEVMPD) and Identification of Medicinal Products (IDMP) Extensive expertise in electronic submission requirements and processes in Europe and US gained from pivotal involvements throughout their development and successful implementation. Extensive experience of the Product Information Management (PIM) programme gained as industry lead since its inception. Extensive network and reputation with regulators, industry, service providers and software vendors working in these spaces
Follow Andrew Marr:
About Marr Consultancy: Marr Consultancy Ltd provides consulting services to the pharmaceutical industry.
George Vincent
Director Of Ecommerce of Materia
Follow George Vincent:
About Materia, Post & Place: Materia engaging in manufacturing, distribution, and customer acquisition in the global cannabis market.
Lesley Wise
Managing Director of Wise Pharmacovigilance & Risk Management
Lesley Wise has more than 15 years of experience in pharmacovigilance both in medicines regulation at at the MHRA, and in the pharmaceutical industry as vice-president and global head of Risk Management Centre of Excellence and Pharmacoepidemiology where she worked closely with colleagues to ensure a companywide approach to Benefit – Risk Management and to maintain compliance with regulatory requirements. Lesley has liaised regularly with regulators, including meetings with PRAC, CHMP and FDA.
Follow Lesley Wise:
About Wise Pharmacovigilance & Risk Management: Wise Pharmacovigilance and Risk Management Ltd is a consultancy service for all pharmaceutical companies.
Shaymaa Taieb
Associate Director, upstream Continious Manufacturing of WuXi Biologics
Follow Shaymaa Taieb:
About WuXi Biologics: WuXi Biologics is a open-access technology platform company offering end-to-end solutions to empower organizations to discover and develop.
Alistair Strachan
Non-Executive Director of Ryboquin
Follow Alistair Strachan:
About ILC Therapeutics: Ryboquin uses its expertise to turn under-developed intellectual property ideas into viable commercial realities.
